By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

The conviction of an ADHD startup founder for over-prescribing Adderall illustrates the danger of optimizing healthcare for conversions. It proves that a doctor's assessment and incentive for quality care is a critical patient safety feature, not a bug to be removed by tech.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

While Retatrutide shows best-in-class weight loss, its potency raises significant safety concerns for real-world use, especially when prescribed via telehealth with limited monitoring. There's a risk that patients, motivated by rapid results, may misuse the drug, making its power a potential danger without close medical supervision.

In a striking case, LifeMD's former Chief Operating Officer sued, alleging inappropriate GLP-1 prescribing by the company's Chief Medical Officer caused him lasting neurological and cognitive decline. This internal conflict highlights the severity of the alleged safety lapses at the highest levels of the company.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

Novo Nordisk and Eli Lilly, after criticizing telehealth companies for unsafe compounded drugs, now partner with and promote platforms like LifeMD, which are accused of questionable prescribing practices. This suggests a potential hypocrisy driven by the need for broad market access for their branded GLP-1s.

Companies like "Prescriberee" operate with a business model targeting life sciences firms as clients. Their goal is not holistic care but efficiently converting interested patients into prescriptions, with one executive citing a 90% conversion rate for eligible patients.